Trisomy 13 Syndrome

SAN DIEGO, April 3, 2023 /PRNewswire/ -- Juno Diagnostics™ (JunoDx™), a company focused on bringing vital health information to patients by improving access, affordability, and transparency, today announced that results of its novel methodology for non-invasive prenatal screening (NIPS) tests were published[AC1] by The American Journal of Obstetrics & Gynecology (AJOG). The Company's novel NIPS approach offers a convenient and affordable avenue to access prenatal care for providers and patients, including those located remotely or within medical deserts. According to the researchers, the Juno Hazel™ tests provide a promising solution to ensure all parents-to-be and families have an equal opportunity to access high-quality prenatal information on their own time and terms. "Publication of these results in The American Journal of Obstetrics & Gynecology is an exciting achievement that further validates our mission to disrupt the current NIPS paradigm," said Dirk van den Boom, Founder and Chief Executive Officer of JunoDx™. "This data clearly demonstrates that capillary blood samples - like those used for our Juno Hazel™ and Hazel™ Plus screens - are a promising option for patients and providers, which we believe will ultimately promote convenient and affordable access to non-invasive prenatal screening tests." Dr. Mathias Ehrich, Co-Founder and Chief Medical Officer of JunoDx™, noted, "I want to acknowledge and thank all the participants in this study and our trusted collaborators for their assistance in the data analysis, including Dr. Christopher K. Ellison, Dr. Allison Chia-Yang, and Mr. Don C. Hutchison. These are important findings that will significantly advance the field of NIPS testing and broaden access for more parents around the globe." About the Juno Hazel™ and Hazel™ Plus Screens The Company's novel approach to NIPS eliminates the need for traditional phlebotomy, a significant barrier to NIPS access. Juno Hazel™ screens for common chromosomal aneuploidies (Down syndrome/trisomy 21, trisomy 18, and trisomy 13) and can also report on fetal sex. Juno Hazel™ Plus also screens for common aneuploidies and fetal sex, including additional analysis for sex chromosome aneuploidies. The Company launched Juno Hazel™ in November 2022 and Juno Hazel™ Plus in January 2023. About Juno Diagnostics™ Juno Diagnostics™ is a category-defining health company bringing vital prenatal health information to patients by combining accessibility, affordability, and transparency. The Company has developed a proprietary Sample Collection Kit and Device to facilitate capillary blood-based testing. Its lead product, the Juno Hazel™ screen, is a non-invasive prenatal screening (NIPS) test that utilizes the proprietary Sample Collection Kit and improves access to high-quality screening results without the high cost, long lead times, and phlebotomy requirements of traditional NIPS. For more information, visit and engage with us on LinkedIn. Investor and Media Contact: Amy Conrad Juniper Point [email protected] 858-366-3243 [AC1] Ehrich M, Sagaser KG, Porreco RP, Bellesheim D, Patil AS, Shulman LP, Van den boom D, Capillary blood collection: Exploring a new method to promote NIPS access, American Journal of Obstetrics and Gynecology (2023), doi: . SOURCE Juno Diagnostics

By Product Segment, The Oligonucleotide-Based Drugs Segment Accounted For The Largest Share Of The Oligonucleotide Synthesis Market. By Application, The Therapeutic Application Segment Accounted For The Largest Share Of The Oligonucleotide Synthesis Market. Fact.MR has projected the oligonucleotide synthesis market to accelerate at an 11.3% CAGR between 2022 and 2032 in comparison to the 11.1% CAGR throughout the historic period. Biotechnology & pharmaceutical companies emerge as key end-users of oligonucleotide synthesis and are poised to register a robust CAGR of 15.5% through 2032. The global oligonucleotide synthesis market is likely to be valued at US$ 5.7 Billion in FY 2022, up from US$ 5.2 Billion in 2021. Demand for oligonucleotide synthesis in therapeutics will continue to thrive, with a documented CAGR of 18.4% during the 2015-2021 historical period of assessment, while demand for oligonucleotide synthesis in research proliferated at a rate of 10.0% during the same period. North America will dominate the global market, registering a growth opportunity worth US$ 2.25 Billion from 2022 to 2032. Get Sample PDF Brochure with " Oligonucleotide Synthesis Market Analysis by Product (Reagents & Consumables, Equipment, Synthesized Oligonucleotides, DNA Oligonucleotides, RNA Oligonucleotides), by Application (Research, Therapeutics), by End-User & by Region - Global Insights 2022-2032" at, Key Takeaways: North America continues to reign supreme in the oligonucleotide synthesis market, led by the United States & Canada. The Asia Pacific is poised to expand most rapidly amongst all the regional markets during the forecast period, owing to its emergence as the world’s most promising life science research hub. Increasing adoption of oligonucleotide synthesis across homes to small enterprises in China is driving the foresaid market. Department of Biotechnology (DBT), New Delhi, and Council of Scientific and Industrial Research (CSIR), New Delhi are working towards backing activities related to oligonucleotide synthesis. The regional market is expected to multiply at a staggering CAGR of 12.5% to surpass US$ 1.73 Billion throughout the conjecture period. Usage of oligonucleotide synthesis in therapeutics is expected to grow at a stellar CAGR of 18.4% during the forecast period. COVID-19 Impact on the Global Oligonucleotide Synthesis Market COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 has moved from a regional crisis to a global pandemic. The World Health Organization (WHO) officially declared the outbreak of COVID-19 a pandemic. A mix of established pharmaceutical and biopharmaceutical companies, along with the players of the oligonucleotide synthesis market, have stepped forward to contribute to worldwide research efforts by providing oligo products for developing test kits, treatments, and vaccines that target the infection caused by the novel Coronavirus. Recent Developments In 2020, Danaher Corporation (US) opened IDT China, an official business entity, to better serve its customer base in the region, reach out to new customers, and provide easier access to its complete portfolio of industry-leading products. In 2020, Danaher (US) acquired the Biopharma business from General Electric Company's (US) Life Sciences division. This subsidiary is called ‘Cytiva’ and will act as a standalone operating company within Danaher's Life Sciences segment. This acquisition strengthened Danaher’s position in the oligo synthesizer and reagents market. In 2020, Microsynth AG (Switzerland) launched Primer-Probe Sets for SARS-CoV-2. In 2020, LGC Limited (UK) partnered with the Paraná Institute of Molecular Biology (IBMP) (Brazil) to supply reliable, high-quality custom GMP oligonucleotides and molecular products to develop a new molecular test for ZDC (zika, dengue, and chikungunya). In 2019, Thermo Fisher Scientific (US) entered into an agreement with BioNTech SE (Germany). Under the agreement, Thermo Fisher supplies nucleotides, enzymes, and other critical raw materials to support BioNTech's messenger RNA (mRNA) manufacturing platform. The four-year, nonexclusive licensing and supply agreement gives BioNTech rights to use Thermo Fisher's technologies as part of its clinical and commercial manufacturing processes. To Gain In-depth Insights into Oligonucleotide Synthesis Market, Request Methodology at, Competitive Landscape Prominent Oligonucleotide Synthesis providers are reliant on partnerships, collaborations, acquisitions, and new software launches to stay afloat in the global market. Constant innovations to ensure a seamless client-customer relationship are the main focus of prominent market players. In January 2021, Thermo Fisher Scientific Inc., the world leader in serving science, and Groupe Novasep SAS (Novasep), a leading supplier of services and technologies for the life sciences industry announced that Thermo Fisher has completed the acquisition of Henogen S.A., Novasep’s viral vector manufacturing business in Belgium for approximately 725 Million Euros in cash. In June 2019, CordenPharma International and GE Healthcare’s Dharmacon Business have entered a strategic collaboration to create an end-to-end solution for oligonucleotide-based drug discovery. The collaboration addressed the speed and capacity challenges researchers face when transitioning from research and preclinical stages to drug development and clinical trials. Key Segments Covered in the Oligonucleotide Synthesis Industry Survey Oligonucleotide Synthesis by Product: Oligonucleotide Synthesis Reagents & Consumables Oligonucleotide Synthesis Equipment Synthesized Oligonucleotides: DNA Oligonucleotides RNA Oligonucleotides Other Oligonucleotide Synthesis Products Oligonucleotide Synthesis by Application: Research Polymerase Chain Reaction (PCR) Next-Generation Sequencing Others Therapeutics Antisense Oligonucleotides Nucleic Acid Aptamers Diagnostics Oligonucleotide Synthesis by End User: Biotechnology & Pharmaceutical Companies Research Institutes Diagnostic Laboratories Oligonucleotide Synthesis by Region: North America Latin America Europe Asia Pacific Middle East & Africa For Critical Insights on this Market, Request for More Info at, Explore Fact.MR’s Coverage on the Healthcare Domain DNA Polymerase Market - DNA polymerase is a unique Pyrococcus-like proofreading enzyme fused to the Sso7d dsDNA-binding protein to create a thermostable fusion polymerase that accurately amplifies long products from a variety of DNA templates. High-fidelity PCR enzymes are used for applications requiring high accuracy during DNA amplification such as sequencing, cloning, or mutagenesis. DNA Mass Ladder Market - DNA Mass Ladder are in a way unique, versatile, and used widely in academic research labs, biopharmaceutical companies, and diagnostic centers. Antibodies used in the DNA Mass Ladder show high specificity against respective mycotoxin. Moreover, in downstream processing, the chromatographic results are consistent with zero interfering signals and recovery yield percentage are high in complex samples. DNA Probes based Diagnostics Market - The growing adoption of DNA probes in new disease identification has led to investments and foray of new players. Fact.MR, a global research and consulting firm, in its new report analyzes the DNA probes based diagnostics market in detail, offering comprehensive coverage on the key success factors. Cell-Free Fetal DNA Testing Market - The DNA from the mother and the fetus is extracted to detect chromosomal disorders such as downs syndrome, trisomy 13, trisomy 18 or any abnormality in the sex chromosome. Manufacturers of the cell-free fetal DNA testing products are focusing on developing new testing methods to prevent chromosomal abnormalities in infants. mRNA Sequencing Market - According to the latest research by Fact.MR, the mRNA Sequencing market is set to witness steady growth during 2021-2031. The market has been a highly fragmented market developing at a gradual rate and is expected to witness lucrative growth with the increasing utilization of methodologies by major participants; the market is anticipated to increase over the projected skyline. Nucleic Acid Extraction System Market - Growing demand for nucleic acid extraction systems in hospitals & diagnostic centers is attributed to rising research initiatives, use of nucleic acid testing in molecular diagnostics, and high requirement for rapid and precise disease diagnosis. About Us: Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner. Contact: Mahendra Singh US Sales Office: 11140 Rockville Pike Suite 400 Rockville, MD 20852 Email: sales@factmr.com Tel: +1 (628) 251-158

Study Shows High Positive Predictive Values in Detecting Common Chromosomal Aneuploidies in All Women, Including Women Under 35 Years of Age SAN CARLOS, Calif., Feb. 19, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, presented data at the Society for Maternal-Fetal Medicine (SMFM) Annual Pregnancy Meeting showing strong clinical performance of its Panorama® SNP-based non-invasive prenatal test (NIPT) to detect common chromosomal aneuploidies (genetic abnormalities) in all women, including women under 35 years of age, with high accuracy.1 The primary objective of the study was to prospectively analyze the clinical performance of the company's NIPT as a part of its rigorous laboratory-based quality assurance program. Fetal outcome data was solicited from women who received a high-risk result from over 900,000 Panorama tests performed between 2013 and 2017. The positive predictive value (PPV) in this cohort was 95.2% for trisomy 21 (Down syndrome), 93.5% for trisomy 18 (Edwards syndrome), 77.9% for trisomy 13 (Patau syndrome), and 86.7% for monosomy X. The PPV was similar for both high-risk (maternal age ≥ 35 yrs) and average risk (< 35 yrs) pregnancies, consistent with a previous study (n=17,885).2 "The high positive predictive values demonstrated in this study once again validate the utility of NIPT as a primary prenatal screening tool in the management of all pregnancies, including women under 35 years of age," said Dr. Kimberly A. Martin, Natera Vice President, Global Women's Health. "We believe this study continues to reaffirm NIPT as the most accurate screening option for pregnant women of all ages." About Panorama® Panorama reveals a baby's risk for severe genetic disorders as early as nine weeks into pregnancy. The test uses a unique single-nucleotide polymorphism (SNP)-based technology to analyze fetal/placental DNA obtained through a blood draw from the mother. It is the only test that differentiates between maternal and fetal DNA in the relevant chromosomes of interest. The test also screens twin pregnancies for zygosity, fetal sex of each baby, and identifies risk for more genetic conditions in twin pregnancies than any other NIPT. Panorama is one of several genetic screening tests from Natera designed to help families on the path to parenthood. This test was developed by Natera, Inc., a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. About Natera Natera is a global leader in cell-free DNA testing. The mission of the company is to change the management of disease worldwide. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, Calif. It offers a host of proprietary genetic testing services to inform physicians who care for pregnant women, researchers in cancer including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. Follow Natera on LinkedIn and Twitter. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, our ability to successfully increase demand for and grow revenues for our product offerings, whether the results of clinical studies will support the use of our product offerings, our expectations of the reliability, accuracy and performance of our screening tests, or of the benefits of our screening tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at and . Natera Contacts Investor Relations: Mike Brophy, CFO, Natera, 650-249-9090 Media: Andrea Sampson, Sullivan & Sampson, 714-374–6174, asampson@sullivanpr.com References DiNonno W, Norvez A, Parmar S, et al. High-Risk Case Results from a Quality Assurance (QA) Program Monitoring Single-Nucleotide Polymorphism (SNP)-Based NIPT Performance. Poster presented at: Society for Maternal-Fetal Medicine Annual Pregnancy Meeting; February 16, 2019; Las Vegas, NV, Poster #929. Dar P, Curnow KJ, Gross SJ, et al. Clinical experience and follow-up with large scale single-nucleotide polymorphism-based noninvasive prenatal aneuploidy testing. Am J Obstet Gynecol 2014;211:527.e1-17. View original content to download multimedia: SOURCE Natera, Inc. Company Codes: NASDAQ-NMS:NTRA